Lantheus Holdings, Inc.(LNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LNTH Lantheus Holdings, Inc.

盘前交易 08-28 06:47:28 EDT

100.47

-0.35

-0.35%

最高101.04	最低100.37	成交量162.30万
今开100.85	昨收100.82	日振幅0.66%
总市值65.41亿	流通市值58.81亿	总股本6,510万
成交额1.64亿	换手率2.77%	流通股本5,853万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LNTH","market":"US","secType":"STK","nameCN":"Lantheus Holdings, Inc.","latestPrice":100.47,"timestamp":1787860800000,"preClose":100.82,"halted":0,"volume":1622961,"delay":0,"changeRate":-0.0034715334259075017,"floatShares":58531500,"shares":65102599,"eps":4.161248,"marketStatus":"盘前交易","change":-0.35,"latestTime":"08-28 06:47:28 EDT","open":100.85,"high":101.04,"low":100.37,"amount":163618456.16358,"amplitude":0.006646,"askPrice":102.49,"askSize":23,"bidPrice":100.02,"bidSize":40,"shortable":3,"etf":0,"ttmEps":4.161248,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787923800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1435204800000,"exchange":"NASDAQ","adjPreClose":100.47,"postHourTrading":{"tag":"盘后","latestPrice":100.47,"preClose":100.47,"latestTime":"19:30 EDT","volume":12998,"amount":1305906.956,"timestamp":1787873404482,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2648717578315163,"impliedVol":0.032,"impliedVolPercentile":0.02},"requestUrl":"/m/hq/s/LNTH","defaultTab":"news","newsList":[{"id":"1142159192","title":"Lantheus宣布FDA批准Tauklarify™（氟喹他F18注射液）——阿尔茨海默病F18标记tau蛋白PET成像试剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1142159192","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142159192?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:02","pubTimestamp":1786708929,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.（简称Lantheus）近日宣布，美国食品药品监督管理局（FDA）已正式批准其新药Tauklarify™（Florquinitau F 18 Injection，即氟喹他F18注射液）。该药物是一种采用F18标记的tau蛋白正电子发射断层扫描（PET）成像试剂，专门用于阿尔茨海默病的诊断与评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH","BK4585","BK4588","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108094508","title":"Truist Securities下调Lantheus Holdings评级至持有，目标价从125美元降至102.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108094508","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108094508?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:09","pubTimestamp":1785841749,"startTime":"0","endTime":"0","summary":"Truist Securities调整了对Lantheus Holdings Inc的评级。该机构将其从“买入”下调至“持有”。同时，目标价也经历了显著削减，从之前的125美元降至102.50美元。这一变动反映出分析师对该公司未来前景的审慎态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4585","BK4588","LNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163034750","title":"Leerink Partners下调Lantheus Holdings评级至“与大盘持平”，目标价从113美元砍至102.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163034750","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163034750?lang=zh_cn&edition=full","pubTime":"2026-08-03 23:14","pubTimestamp":1785770048,"startTime":"0","endTime":"0","summary":"Leerink Partners近日调整了对Lantheus Holdings, Inc.的评级。该机构将其股票评级从“跑赢大盘”下调至“与大盘持平”。与此同时，目标价也遭到大幅削减——从先前的113美元降至102.5美元。这一变动反映出分析机构对该公司未来市场表现的预期趋于谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LNTH","BK4198","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100132658","title":"Lantheus交易拟通过债务与股权组合融资，不附带任何财务条件或其他相关先决条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1100132658","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100132658?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:33","pubTimestamp":1785756788,"startTime":"0","endTime":"0","summary":"Lantheus方面表示，这项交易预计将通过债务与股权的混合方式进行融资。值得注意的是，该交易并不受制于任何财务条件，也不存在其他相关的附带条款或或有事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LNTH","BK4198","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153691195","title":"财报前瞻｜Lantheus Holdings, Inc.本季度营收预计小幅下滑，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1153691195","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153691195?lang=zh_cn&edition=full","pubTime":"2026-07-30 12:22","pubTimestamp":1785385330,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.将于2026年08月06日发布新一季财报，市场预计核心产品动能放缓与费用投入加大交织下，公司盈利能力阶段性承压。近期机构席位的观点总体偏谨慎，占比更高的一方认为短期利润承压与增速回落的组合将成为股价的主要约束。多家知名卖方分析师强调，本季度市场一致预期的营收和EPS同比下滑反映了产品价格与费用投入的双重压力，同时对下半年改善保持观望态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Lantheus Holdings, Inc.本季度营收预计小幅下滑，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184176705","title":"Curium正洽谈以约每股102美元预付，另加每股12.50美元收购Lantheus股份——彭博社消息","url":"https://stock-news.laohu8.com/highlight/detail?id=1184176705","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184176705?lang=zh_cn&edition=full","pubTime":"2026-07-28 05:33","pubTimestamp":1785187993,"startTime":"0","endTime":"0","summary":"据彭博社报道，Curium正在进行谈判，计划以每股约102美元的预付价格，外加每股12.50美元的额外款项，收购Lantheus Holdings, Inc.的股份。这一交易结构显示出收购方对Lantheus价值的认可，并希望通过分阶段支付方式锁定交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LNTH","BK4198","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127404598","title":"Lantheus Holdings：因生产条件问题，FDA无法在2026年6月29日前批准Lnth-2501新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1127404598","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127404598?lang=zh_cn&edition=full","pubTime":"2026-06-27 04:02","pubTimestamp":1782504139,"startTime":"0","endTime":"0","summary":"Lantheus Holdings公司宣布，由于生产条件相关问题，美国食品药品监督管理局（FDA）将无法在先前设定的2026年6月29日这一目标日期前，批准其候选药物Lnth-2501的新药申请（NDA）。这一消息意味着该药物的审批进程将面临延迟。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4588","LNTH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190539000","title":"Lantheus宣布PET诊断成像试剂盒LNTH-2501（Ga 68 Edotreotide）的PDUFA日期延长三个月，该产品靶向生长抑素受体阳性（SSTR+）神经内分泌肿瘤（NETs）","url":"https://stock-news.laohu8.com/highlight/detail?id=1190539000","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190539000?lang=zh_cn&edition=full","pubTime":"2026-03-18 04:04","pubTimestamp":1773777882,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.近日宣布，其针对生长抑素受体阳性神经内分泌肿瘤的PET诊断成像试剂盒LNTH-2501的处方药用户付费法案目标日期已获得美国食品药品监督管理局延长三个月。此次延期为FDA提供了更多时间来完成对该公司新药申请的审查。公司表示，将继续与FDA密切合作，以支持该申请的最终审查。此次PDUFA日期的延长并不反映FDA对该申请的任何负面看法，也不预示最终的审查结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH","BK4585","BK4198","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617382658","title":"Lantheus Holdings, Inc.盘中异动 急速下跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617382658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2617382658?lang=zh_cn&edition=full","pubTime":"2026-03-07 01:26","pubTimestamp":1772818005,"startTime":"0","endTime":"0","summary":"北京时间2026年03月07日01时26分，Lantheus Holdings, Inc.股票出现异动，股价急速下挫5.18%。Lantheus Holdings, Inc.股票所在的制药行业中，整体跌幅为1.27%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。Precision Diagnostic 产品帮助医疗保健专业人员查找和跟踪疾病，重点是心脏病学。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗， 还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030701264597a8c077&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030701264597a8c077&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4198","LNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162262861","title":"异动解读 | Lantheus获FDA药物暂时批准，股价盘中大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162262861","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162262861?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:07","pubTimestamp":1772464036,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.（股票代码：LNTH）今日盘中股价大幅上涨5.07%，引起了市场的高度关注。消息面上，Lantheus Holdings, Inc.宣布其研发的Lutetium Lu 177 Dotatate（研发代号Pnt2003）已获得美国食品药品监督管理局（FDA）的暂时批准。该药物在放射性方面与已上市的Lutathera®具有等效性，这一积极进展被视为公司产品管线的重要里程碑，增强了投资者对其未来增长潜力的信心，从而推动了股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178118628","title":"Lantheus获FDA暂时批准Lutetium Lu 177 Dotatate (Pnt2003)，放射性等效于Lutathera®","url":"https://stock-news.laohu8.com/highlight/detail?id=1178118628","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178118628?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:31","pubTimestamp":1772458282,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.宣布，其研发的Lutetium Lu 177 Dotatate（研发代号Pnt2003）已获得美国食品药品监督管理局（FDA）的暂时批准。该药物在放射性方面与已上市的Lutathera®具有等效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH","BK4585","BK4198","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517943630","title":"Lantheus Holdings, Inc.涨2.00% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943630","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517943630?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:49","pubTimestamp":1741186195,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时49分，Lantheus Holdings, Inc.股票出现波动，股价大幅上涨2.00%。Lantheus Holdings, Inc.股票所在的制药行业中，整体涨幅为0.79%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗，还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224955a260ce20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224955a260ce20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","LNTH","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516548063","title":"Lantheus Holdings, Inc.2024财年实现净利润3.12亿美元，同比减少4.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516548063?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931236,"startTime":"0","endTime":"0","summary":"3月3日，Lantheus Holdings, Inc.公布财报，公告显示公司2024财年净利润为3.12亿美元，同比减少4.59%；其中营业收入为15.34亿美元，同比增加18.36%，每股基本收益为4.52美元。机构评级：截至2025年3月3日，当前有14家机构对Lantheus Holdings, Inc.目标价做出预测，其中目标均价为131.11美元，其中最低目标价为94.50美元，最高目标价为166.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000056abe4aca3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000056abe4aca3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178569921","title":"异动解读 | 2024年业绩超出预期,朗修盘中大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178569921","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178569921?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:43","pubTimestamp":1740581038,"startTime":"0","endTime":"0","summary":"朗修控股(LNTH)今日盘中大涨5.15%,引起了市场的广泛关注。\n\n消息面上,朗修公布了2024年第四季度业绩,每股收益为1.59美元,高于分析师预期的1.53美元,增长3.92%;季度销售额为3.911亿美元,也超出分析师预期的3.754亿美元,增长4.17%。\n\n另外,该公司还发布了2025年的业绩预期,预计全年营收为15.45亿至16.1亿美元,市场之前预期为16.05亿美元;预计调整后每股收益为7.00至7.20美元,高于市场预期的6.95美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856927","title":"Lantheus Holdings, Inc.盘中异动 早盘股价大涨5.35%报84.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856927?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580290,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分，Lantheus Holdings, Inc.股票出现波动，股价大幅拉升5.35%。Lantheus Holdings, Inc.股票所在的制药行业中，整体跌幅为0.13%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗，还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022622313096314f22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022622313096314f22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LNTH","BK4198","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106584934","title":"朗修预期2025年营收为15.45亿至16.1亿美元，市场预期为16.05亿美元，调整后每股收益为7.00至7.20美元，市场预期为6.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106584934","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106584934?lang=zh_cn&edition=full","pubTime":"2025-02-26 20:08","pubTimestamp":1740571700,"startTime":"0","endTime":"0","summary":"朗修预期2025年营收为15.45亿至16.1亿美元，市场预期为16.05亿美元，调整后每股收益为7.00至7.20美元，市场预期为6.95美元。以上内容来自Benzinga Earnings专栏，原文如下：Lantheus Forecasts 2025 Revenues Of $1.545B-$1.61B Vs. Consensus Of $1.605B, With Adjusted EPS Of $7.00-$7.20 Vs. $6.95 Est.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144016372","title":"Lantheus Holdings 2024年第四季度调整后每股收益为$1.59，超出预期的$1.53，销售额为$391.10M，超出预期的$375.43M","url":"https://stock-news.laohu8.com/highlight/detail?id=1144016372","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144016372?lang=zh_cn&edition=full","pubTime":"2025-02-26 20:03","pubTimestamp":1740571427,"startTime":"0","endTime":"0","summary":"Lantheus Holdings  报告其季度每股收益为$1.59，高于分析师预期的$1.53，超出预期3.92%。与去年同期的$1.75相比，这是一个9.14%的下降。与去年同期的$354.00M相比，这一销售额增长了10.48%。以上内容来自Benzinga Earnings专栏，原文如下：Lantheus Holdings  reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $1.53 by 3.92 percent. This is a 9.14 percent decrease over earnings of $1.75 per share from the same period last year.  The company reported quarterly sales of $391.10 million which beat the analyst consensus estimate of $375.43 million by","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Lantheus Holdings 2024年第四季度调整后每股收益为$1.59，超出预期的$1.53，销售额为$391.10M，超出预期的$375.43M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2512196489","title":"Lantheus Holdings, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512196489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512196489?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:49","pubTimestamp":1739904545,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时49分，Lantheus Holdings, Inc.股票出现波动，股价急速上涨5.02%。Lantheus Holdings, Inc.股票所在的制药行业中，整体涨幅为1.84%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。Precision Diagnostic 产品帮助医疗保健专业人员查找和跟踪疾病，重点是心脏病学。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗，还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219024906a24ae2c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219024906a24ae2c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4198","LNTH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510521873","title":"Lantheus Holdings, Inc.盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510521873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510521873?lang=zh_cn&edition=full","pubTime":"2025-02-12 04:43","pubTimestamp":1739306624,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日04时43分，Lantheus Holdings, Inc.股票出现波动，股价急速下跌5.09%。Lantheus Holdings, Inc.股票所在的制药行业中，整体涨幅为0.07%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。Precision Diagnostic 产品帮助医疗保健专业人员查找和跟踪疾病，重点是心脏病学。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗，还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120443459881f7fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120443459881f7fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LNTH","BK4198","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508853129","title":"Lantheus Holdings, Inc.盘中异动 快速下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508853129","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508853129?lang=zh_cn&edition=full","pubTime":"2025-02-04 01:59","pubTimestamp":1738605560,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日01时59分，Lantheus Holdings, Inc.股票出现异动，股价大幅跳水5.08%。Lantheus Holdings, Inc.股票所在的制药行业中，整体跌幅为0.24%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。Precision Diagnostic 产品帮助医疗保健专业人员查找和跟踪疾病，重点是心脏病学。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗，还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204015921a2383257&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204015921a2383257&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4198","LNTH","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lantheus.com","stockEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":-0.0211},{"period":"3month","weight":0.0118},{"period":"6month","weight":0.3412},{"period":"1year","weight":0.7676},{"period":"ytd","weight":0.5097}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0408},{"period":"3month","weight":0.0193},{"period":"6month","weight":0.1241},{"period":"1year","weight":0.1925},{"period":"ytd","weight":0.1308}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lantheus Holdings, Inc.成立于1956年，总部在马萨诸塞州的北比尔里卡。公司是从事开发、生产、销售及分销创新医学影像诊断试剂和产品，协助临床医生在心血管和其他疾病的诊断的全球领导者。公司的试剂通常用于诊断冠状动脉疾病、充血性心脏衰竭、中风、外周血管疾病和其他疾病。临床医生使用公司的显像剂和产品通过一系列的成像方式,包括核成像、超声心动图和磁共振成像,或核磁共振。公司相信改进的诊断信息能够使医疗服务提供更好的检测和表征,或排除疾病,可能实现改善病人状况、减少病人风险和限制纳税人整体成本和整个医疗体系。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":-0.020476},{"month":2,"riseRate":0.727273,"avgChangeRate":0.191228},{"month":3,"riseRate":0.636364,"avgChangeRate":0.020084},{"month":4,"riseRate":0.909091,"avgChangeRate":0.077963},{"month":5,"riseRate":0.636364,"avgChangeRate":0.022807},{"month":6,"riseRate":0.727273,"avgChangeRate":0.132742},{"month":7,"riseRate":0.5,"avgChangeRate":0.028487},{"month":8,"riseRate":0.5,"avgChangeRate":0.060337},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.049956},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.045273},{"month":11,"riseRate":0.818182,"avgChangeRate":0.076347},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.040744}],"exchange":"NASDAQ","name":"Lantheus Holdings, Inc.","nameEN":"Lantheus"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lantheus Holdings, Inc.(LNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Lantheus Holdings, Inc.(LNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Lantheus Holdings, Inc.,LNTH,Lantheus Holdings, Inc.股票,Lantheus Holdings, Inc.股票老虎,Lantheus Holdings, Inc.股票老虎国际,Lantheus Holdings, Inc.行情,Lantheus Holdings, Inc.股票行情,Lantheus Holdings, Inc.股价,Lantheus Holdings, Inc.股市,Lantheus Holdings, Inc.股票价格,Lantheus Holdings, Inc.股票交易,Lantheus Holdings, Inc.股票购买,Lantheus Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lantheus Holdings, Inc.(LNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Lantheus Holdings, Inc.(LNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}